11:00 AM EST, 11/17/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday that new data from a phase 3b study showed its Tremfya treatment continued to reduce signs and symptoms of active psoriatic arthritis.

The company said that treatment with Tremfya in active psoriatic arthritis patients demonstrated two and a half times greater ability to inhibit joint structural damage compared with the placebo by the end of 24 weeks, sustained through 48 weeks.

It said that over half the patients treated with Tremfya in both dose groups, once every four weeks and once every eight weeks, displayed a 50% improvement in signs and symptoms of psoriatic arthritis by the end of 48 weeks.

Shares of the company were up 1.6% in recent Monday trading.

Price: 199.02, Change: +3.09, Percent Change: +1.58